May 9, 2017 | Hong Kong-based investment firm AID Partners Capital Ltd will acquire Israeli medical diagnostic company GeneSort for $23 million. The deal will provide GeneSort with additional resources and support as is seeks to expand into Southeast Asia and other global markets. Moshe Hogeg’s tech focused venture capital firm Singulariteam fund is the largest investor in GeneSort, having invested $2.2 million in the company. GeneSort is a molecular diagnostics company focused on integrating molecular genomics with personalized therapeutic approaches. GeneSort also recently signed a development contract with the government of Malta, and also won a contract with the Israeli government to deploy diagnostic testing in the country.